Cargando…
Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury
Myocardial ischemia/reperfusion (I/R) injury is a major cause of mortality and morbidity worldwide. Among factors contributing to I/R injury, proteolytic enzymes could also cause cellular injury, expand the injured area and induce inflammation, which then lead to cardiac dysfunction. Therefore, prot...
Autores principales: | Mongkolpathumrat, Podsawee, Kijtawornrat, Anusak, Prompunt, Eakkapote, Panya, Aussara, Chattipakorn, Nipon, Barrère-Lemaire, Stephanie, Kumphune, Sarawut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070046/ https://www.ncbi.nlm.nih.gov/pubmed/33924676 http://dx.doi.org/10.3390/biomedicines9040422 |
Ejemplares similares
-
Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion
por: Mongkolpathumrat, Podsawee, et al.
Publicado: (2022) -
Gelatin-coated silicon oxide nanoparticles encapsulated recombinant human secretory leukocyte protease inhibitor (rhSLPI) reduced cardiac cell death against an in vitro simulated ischaemia/reperfusion injury
por: Pikwong, Faprathan, et al.
Publicado: (2023) -
Endothelial-Cell-Derived Human Secretory Leukocyte Protease Inhibitor (SLPI) Protects Cardiomyocytes against Ischemia/Reperfusion Injury
por: Kongpol, Kantapich, et al.
Publicado: (2019) -
Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non-obese type 2 diabetic Goto-Kakizaki rats
por: Sanit, Jantira, et al.
Publicado: (2019) -
The cardioprotective effects of secretory leukocyte protease inhibitor against myocardial ischemia/reperfusion injury
por: Prompunt, Eakkapote, et al.
Publicado: (2018)